News | May 30, 2012

Tryton Announces Positive Clinical Data From More Than 900 Patients Treated With Bifurcation Stent

Pooled analysis of results examines evidence from eight clinical studies

May 30, 2012 Tryton Medical Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced results of a patient-level pooled analysis of six-month clinical outcomes of the Tryton Side Branch Stent. Findings were presented last week in Paris at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.

Data from 905 patients treated with the Tryton stent in eight European post-marketing registries demonstrated low target lesion revascularization rates of 2.9% at six months and 4% at one year, and a low 0.5% thrombosis rate at one year.

“The consistently excellent results for the Tryton stent system in hundreds of patients should provide physicians with a great deal of confidence when choosing a strategy for treating bifurcation lesions,” said EuroPCR course director William Wijns, M.D., of the Cardiovascular Center in Aalst, Belgium. “In study after study, the Tryton stent has shown positive and predictable results for these complex cases, and this solution allows Tryton to challenge the dogma of provisional stenting for the treatment of bifurcation lesions whenever larger side branches are involved.”

Results of the pooled analysis were featured in a “Tools and Techniques” session chaired by Wijns and Martin B. Leon, M.D., of Columbia University, New York. The session featured two successful live case transmissions using the Tryton stent, including a left main bifurcation, by Eulogio Garcia, M.D., of the Hospital Clinico San Carlos in Madrid, Spain.

“For me, the key benefit of the Tryton stent is predictability,” said Garcia. “Using the Tryton, you can predict that at the end of the procedure you will have good results in both the side branch and the main vessel. In addition, there is no question that the Tryton stent has simplified the treatment of distal bifurcation of the left main.”

“Tryton Medical is emerging as the clear leader in bifurcation treatment, evidenced by an impressive presence at EuroPCR, where three live Tryton case transmissions were performed, 14 Tryton case reports discussed, and three Tryton clinical abstracts presented. We also announced our 5,000th implant, demonstrating deep adoption and routine use in clinical practice,” said Shawn P. McCarthy, president and CEO of Tryton Medical. "The Tryton Side Branch Stent represents a new growth driver in interventional cardiology. In addition to offering an innovative solution for bifurcations, our device holds potential for left main disease, which could generate a combined market opportunity of approximately 700,000 procedures annually worldwide.”

For more information: www.trytonmedical.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init